EC green lights Gavreto for RET fusion-positive advanced NSCLC

20 November 2021
2020_roche_big

The European Commission (EC) has granted conditional marketing authorization for Gavreto (pralsetinib) as a monotherapy for the treatment of adults with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.

Developed by Swiss pharma giant Roche (ROG: SIX) and Blueprint Medicines (Nasdaq: BPMC), Gavreto is the first and only precision medicine approved in the European Union for the first-line treatment of people with RET fusion-positive advanced NSCLC.

The drug was approved in the USA for this indication in September last year and also for transfection (RET) fusion-positive NSCLC). SVB Leerink Research analysts forecasts peak annual US Gavreto revenues of ~$887 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology